[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 234,523
  • Shares Outstanding, K 17,106
  • Annual Sales, $ 18,760 K
  • Annual Income, $ -684,630 K
  • EBIT $ -60 M
  • EBITDA $ -60 M
  • 60-Month Beta N/A
  • Price/Sales 6.43
  • Price/Cash Flow N/A
  • Price/Book 1.02

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 37.58%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 118.84% on 09/05/25
  • IV Low 0.00% on 08/20/26
  • Expected Move (DTE 0) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 14
  • Volume Avg (30-Day) 17
  • Put/Call OI Ratio 8.41
  • Today's Open Interest 16,085
  • Open Int (30-Day) 16,108
  • Expected Range 14.43 to 14.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-1.70
  • Number of Estimates 1
  • High Estimate $-1.70
  • Low Estimate $-1.70
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.13 +21.11%
on 07/29/26
13.88 -2.85%
on 08/20/26
+1.72 (+14.63%)
since 07/20/26
3-Month
11.13 +21.11%
on 07/29/26
14.14 -4.63%
on 05/28/26
+0.76 (+5.97%)
since 05/20/26

Most Recent Stories

More News
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

SAN DIEGO , Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics...

RNA : 13.48 (-1.68%)
BMY : 65.47 (-3.17%)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment...

RNA : 13.48 (-1.68%)
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome

-- ATR 1072 is the company's first precision cardiology program to enter the clinic --

RNA : 13.48 (-1.68%)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment...

RNA : 13.48 (-1.68%)
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

SAN DIEGO , April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...

RNA : 13.48 (-1.68%)
BMY : 65.47 (-3.17%)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO , April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment...

RNA : 13.48 (-1.68%)
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform

RNA : 13.48 (-1.68%)
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 13.48 (-1.68%)
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders

SAN DIEGO , Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 13.48 (-1.68%)
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing

RNA : 13.48 (-1.68%)

Business Summary

Atrium Therapeutics Inc. is pioneering targeted delivery of ribonucleic acid therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The company's pipeline consists of precision cardiology candidates, ATR 1072 and ATR 1086. Atrium Therapeutics Inc. is based...

See More

Key Turning Points

3rd Resistance Point 14.51
2nd Resistance Point 14.19
1st Resistance Point 13.84
Last Price 13.48
1st Support Level 13.16
2nd Support Level 12.84
3rd Support Level 12.49

See More

52-Week High 16.77
Fibonacci 61.8% 14.62
Fibonacci 50% 13.95
Last Price 13.48
Fibonacci 38.2% 13.28
52-Week Low 11.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.